Reata Pharmaceuticals (NASDAQ:RETA) PT Lowered to $67.00 at LADENBURG THALM/SH SH

Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price objective lowered by LADENBURG THALM/SH SH from $75.00 to $67.00 in a report released on Wednesday, The Fly reports.

A number of other equities analysts have also recently issued reports on the stock. The Goldman Sachs Group raised shares of Reata Pharmaceuticals from a neutral rating to a buy rating and increased their price objective for the stock from $34.00 to $91.00 in a research report on Thursday, March 24th. StockNews.com began coverage on shares of Reata Pharmaceuticals in a report on Thursday, March 31st. They issued a sell rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $109.13.

Shares of RETA opened at $24.54 on Wednesday. The stock has a market capitalization of $893.26 million, a P/E ratio of -2.94 and a beta of 1.25. The firm’s fifty day simple moving average is $31.48 and its two-hundred day simple moving average is $43.19. Reata Pharmaceuticals has a 12 month low of $20.24 and a 12 month high of $153.41.

Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($2.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.23. The company had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.55 million. Reata Pharmaceuticals had a negative net margin of 2,650.72% and a negative return on equity of 137.52%. The business’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.86) EPS. As a group, research analysts forecast that Reata Pharmaceuticals will post -8.57 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Verition Fund Management LLC purchased a new stake in Reata Pharmaceuticals in the 1st quarter valued at about $2,724,000. Charles Schwab Investment Management Inc. increased its stake in Reata Pharmaceuticals by 3.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 200,153 shares of the company’s stock valued at $6,558,000 after buying an additional 6,526 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Reata Pharmaceuticals during the 1st quarter worth approximately $317,000. Vanguard Group Inc. increased its stake in shares of Reata Pharmaceuticals by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 2,643,082 shares of the company’s stock worth $86,587,000 after purchasing an additional 85,409 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Reata Pharmaceuticals by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 15,591 shares of the company’s stock worth $511,000 after purchasing an additional 5,754 shares during the last quarter. Hedge funds and other institutional investors own 73.55% of the company’s stock.

Reata Pharmaceuticals Company Profile (Get Rating)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Further Reading